Cite

HARVARD Citation

    Schuler, M. et al. (2019). Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study. Lancet oncology. 20 (10), pp. 1454-1466. [Online]. 
  
Back to record